Telisotuzumab Vedotin, an antibody-drug conjugate with MET as the target, was recently approved (based on the LUMINOSITY trial) to treat NSCLC patients with high MET protein overexpression (≥50% of tumor cells with strong/3+ staining) who have received a prior systemic therapy (Camidge et al., 2024). The gene discussed is MET; the disease is neoplasm.